富马酸喹硫平与氯丙嗪治疗68例慢性精神分裂症对照研究

The study of the efficacy and safety of quetiapine and chlorpromszine in the treatment of chronic schizophrenia

目的:比较喹硫平与氯丙嗪治疗慢性精神分裂症的疗效和安全性。方法:将68例慢性精神分裂症患者随机分两组,分别以喹硫平和氯丙嗪治疗,疗程8周。采用阳性与阴性症状量表(PANSS)及副反应量表(TESS)评定疗效及不良反应。结果:治疗8周后,两组PANSS总评分均较治疗前显著下降。但是,喹硫平组阴性症状评分的下降要高于氯丙嗪组,两者有显著性差异(P<0.05),且喹硫平组的不良反应要低于氯丙嗪组(P<0.05)。结论:喹硫平与氯丙嗪治疗慢性精神分裂症患者对阴性症状优于氯丙嗪,不良反应轻、安全性好。

Objective：to compare the efficacy and safety of quetiapine and chlorpromszine in the treatment of chronic schizophrenia. Methods：68 patients with chronic schizophrenia（ according to ICD -10） were divided into two groups who treated with quetiapine or chlorpromszine respectively for 8 weeks. The positive and negative syndrome scale （PNASS） and treatment emergent side effect scale （TESS） were used to evaluate efficacy and adverse effect before an after treatment repectively. Results： There was significant differences between before and after the treatment of two groups in overall response showed by the reduction of the scores of total scale of PANSS at $ weeks treatment. But, the scores of negative syndrome of PANSS in queteapine group was significantly lower than in chlorpromszine group at 8 week after treatment （ P 〈 0.05 ） , so do the sores of TESS. Conclusions ： The efficacy on negative syn drome of quetiapine is better than that of chlorpromszine , and quetiapine have fewer side effects than chlorpromszine in the treatment of chronic schizophrenia.